2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Garrett A, Marcom P, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz R, Rimawi M, Abramson V, Pohlmann P, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Waks A, DeMeo M, Burstein H, Partridge A, Dell'Orto P, Russo L, Krause E, Newhouse D, Kurt B, Mittendorf E, Schneider B, Prat A, Winer E, Krop I, Tolaney S, Investigators T, Barroso-Sousa R, Curigliano G, DiLullo M, Hui W, Kirkup C, Viale G, Zheng Y. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. Journal Of Clinical Oncology 2024, 42: 3652-3665. PMID: 38935923, PMCID: PMC11527383, DOI: 10.1200/jco.23.02170.Peer-Reviewed Original ResearchInvasive disease-free survivalRecurrence-free intervalAdjuvant T-DM1T-DM1Long-term outcomesBreast cancerStage I HER2-positive breast cancerInvasive disease-free survival eventsLong-term outcomes of patientsBreast cancer-specific survivalHER2-positive breast cancerAdjuvant trastuzumab emtansinePredictors of thrombocytopeniaRisk scoreT-DM1 armCancer-specific survivalHormone receptor statusHigh-risk tumorsDisease-free survivalMedian follow-upClinically relevant toxicitiesRisk of recurrenceOutcomes of patientsHER2 immunohistochemical scoresTH arm
2023
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
Waks A, Ogayo E, Paré L, Marín-Aguilera M, Brasó-Maristany F, Galván P, Castillo O, Martínez-Sáez O, Vivancos A, Villagrasa P, Villacampa G, Tarantino P, Desai N, Guerriero J, Metzger O, Tung N, Krop I, Parker J, Perou C, Prat A, Winer E, Tolaney S, Mittendorf E. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. JAMA Oncology 2023, 9: 835-840. PMID: 37103927, PMCID: PMC10141272, DOI: 10.1001/jamaoncol.2023.0181.Peer-Reviewed Original ResearchConceptsPathologic complete responseNeoadjuvant therapyPCR scoresNeoadjuvant paclitaxelBreast cancerPrognostic studiesRisk scoreLikelihood of pCRPretreatment tumor biopsy samplesErbB2-positive breast cancerBaseline tumor samplesLimited clinical featuresFavorable survival outcomesHormone receptor statusPositive breast cancerPrognostic risk scoreTumor biopsy samplesPaclitaxel weeklyComplete responsePCR rateReceptor statusClinical featuresMean ageSurvival outcomesRecurrence events
2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Gelber RD, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M, Committee and Investigators A. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. European Journal Of Cancer 2022, 166: 219-228. PMID: 35313167, DOI: 10.1016/j.ejca.2022.01.031.Peer-Reviewed Original ResearchConceptsSubpopulation treatment effect pattern plotInvasive disease-free survivalComposite risk scoreAdjuvant pertuzumabAPHINITY trialTIL percentageBreast cancerRisk scoreSubpopulation treatment effect pattern plot analysisEarly HER2-positive breast cancerDisease-free survival benefitHER2-positive breast cancerTreatment effectsNode-positive cohortDisease-free survivalEarly breast cancerNodal statusSurvival benefitLymphocyte percentagePatient subpopulationsComposite riskPatientsCovariates of interestChemotherapyPertuzumab